Type two diabetes Nutritional, Metabolic, Endocrine Diabetes
Conditions
Interventions
Patients will receive either:
1. Atorvastatin 10 - 20 mg/d
2. Gemfibrozil 900 - 1200 mg/d
For 12 weeks, and then will receive:
3. 10 mg
Sponsors
Hospital Sant Pau (Spain)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Men and women with type two diabetes, aged 35 to 75 years 2. No treatment known to interfere with lipid metabolism (nonselective B-blockers, high dose diuretics, systemic steroids, lipid-lowering drugs) in the month preceding inclusion in the study 3. Plasma Low Density Lipoprotein cholesterol (LDLc) greater than 100 mg/dl (2.6 mmol/litre), and triglycerides less than 400 mg/dl (4.51mmol/litre)
Exclusion criteria
Exclusion criteria: 1. Pregnant 2. No reliable contraceptive method was used 3. Serum creatinine more than 1.7 mg/dl (150 umol/litre) 4. Hepatic dysfunction (transaminases greater than 1.5 times upper normal limit at inclusion) 5. Creatine kinase more than three times the upper normal limit 6. Acute or chronic disorders that might interfere with compliance
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Effect on components of diabetic dyslipidaemia (especially apoB and LDL size). | — |
Secondary
| Measure | Time frame |
|---|---|
| Concentrations of inflammatory markers. | — |
Countries
Spain
Outcome results
None listed